MedPath
FDA Approval

Xeomin

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
September 14, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Botulinum toxin type A(50 [USP'U] in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Merz Pharma GmbH & Co. KGaA

Merz North America, Inc.

342543051

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Xeomin

Product Details

NDC Product Code
46783-165
Application Number
BLA125360
Marketing Category
BLA (C73585)
Route of Administration
INTRAMUSCULAR
Effective Date
September 14, 2023
SucroseInactive
Code: C151H8M554Class: IACT
Code: E211KPY694Class: ACTIBQuantity: 50 [USP'U] in 1 1
Albumin HumanInactive
Code: ZIF514RVZRClass: IACT

Xeomin

Product Details

NDC Product Code
46783-161
Application Number
BLA125360
Marketing Category
BLA (C73585)
Route of Administration
INTRAMUSCULAR
Effective Date
September 14, 2023
Code: E211KPY694Class: ACTIBQuantity: 50 [USP'U] in 1 1
Albumin HumanInactive
Code: ZIF514RVZRClass: IACT
SucroseInactive
Code: C151H8M554Class: IACT

Xeomin

Product Details

NDC Product Code
46783-160
Application Number
BLA125360
Marketing Category
BLA (C73585)
Route of Administration
INTRAMUSCULAR
Effective Date
September 14, 2023
Code: E211KPY694Class: ACTIBQuantity: 100 [USP'U] in 1 1
Albumin HumanInactive
Code: ZIF514RVZRClass: IACT
SucroseInactive
Code: C151H8M554Class: IACT
© Copyright 2025. All Rights Reserved by MedPath